Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
January 2022
Inhibition de la progression des lésions articulaires structurelles avec l'upadacitinib dans la polyarthrite rhumatoïde : résultats à un an du programme de phase 3 SELECT
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
.Keywords:
February 2021
Upadacitinib en Monothérapie Versus Méthotrexate en Monothérapie Chez des Patients Japonais Méthotrexate-naïfs et Atteints de Polyarthrite Rhumatoïde : une Sous-Analyse de l'Étude de Phase 3 SELECT-EARLY
Mod Rheumatol 2021;26:1–16.
In this sub-analysis of the Phase 3 SELECT-EARLY study, UPA demonstrated clinical efficacy superior to placebo in the Japanese subpopulation. Along with a favourable efficacy observed with the Japan-specific 7.5 mg dose of UPA for all secondary endpoints. SELECT-EARLY was designed to study the safety and efficacy of UPA 15 and 30mg as monotherapy, but it also included a subset of 138 Japanese patients, 40% of whom were randomised to receive UPA 7.5mg. This was designed to meet the requirements o...
August 2020
Efficacité et Innocuité de l’Upadacitinib en Monothérapie Chez les Patients Méthotrexate-Naïfs Avec une Polyarthrite Rhumatoïde Modérément À Sévèrement Active (Select-early) : Un Essai Randomisé, en Double Aveugle, À Comparateur Actif, Multicentrique et Multinational
Arthritis Rheumatol 2020
Upadacitinib monotherapy demonstrated superior clinical, radiographic, and patient-reported outcomes versus methotrexate in methotrexate-naïve RA patients.This 48-week double-blind active comparator study investigated upadacitinib monotherapy in patients with early RA, who were either methotrexate-naïve, or who had very limited exposure. 947 patients were randomised to once-daily upadacitinib 15 or 30 mg, or weekly methotrexate. Unusually, there were two separate primary endpoints, selected for ...